Nature Reviews Gastroenterology & Hepatology (@natrevgastrohep.nature.com)

ICYMI: New online! Redefining gastroesophageal junction cancer care with perioperative immunotherapy, minimal residual disease monitoring and new targets

loading . . .

Redefining gastroesophageal junction cancer care with perioperative immunotherapy, minimal residual disease monitoring and new targets Nature Reviews Gastroenterology & Hepatology, Published online: 18 December 2025; doi:10.1038/s41575-025-01165-6Gastric and gastroesophageal junction adenocarcinoma remains a major global health challenge, with a rising incidence among younger individuals worldwide despite advances in biomarker-directed targeted therapies and immunotherapy. Current breakthroughs include perioperative immunotherapy, HER2-directed therapy sequencing and a decisive shift towards biomarker-driven treatment. https://www.nature.com/articles/s41575-025-01165-6?utm_source=bluesky&utm_medium=social&utm_campaign=nrgastro